2022 Healthcare Leads Pharmacology 
European Pharmaceutical Review
JULY 13, 2023
1,2 Moreover, except for countries such as Czechia, Denmark and Germany, the cost of these medications is borne by the patient, rather than national insurance or healthcare systems. This could lead to significant research waste. Expert Review of Clinical Pharmacology. British journal of pharmacology. Mechoulam R.
pharmaphorum
JANUARY 26, 2023
2022 was a banner year for genomics. And in the UK specifically, genomics remained high on the national agenda, with several significant government programmes and investments announced – including the Newborn Genomes Programme in healthcare and the Precision Breeding Bill in the agricultural sector.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MAY 2, 2023
Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. billion in 2022, the average projected return on investment (ROI) in R&D was just 1.2 1,2 In the EU, an estimated 2.7 Available from: [link] Worldwide cancer statistics [Internet].
pharmaphorum
JANUARY 16, 2023
The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023.
Map My Customers
MARCH 31, 2022
As a pharmaceutical sales rep, there are appointments and meetings with doctors and professionals that need to stay up to date with the latest pharmacology treatment options for their patients. Pharmaceutical sales representatives will be the face of the company for drug and treatment manufacturers.
Pharmaceutical Technology
NOVEMBER 3, 2022
There, Boehringer had earlier warned of the impending alteplase shortage in April 2022. This is due to aging populations around the world, which leads to an increased risk of such conditions, explains Craig Beavers, PhD, assistant professor at the University of Kentucky’s College of Pharmacy in Lexington.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Expert insights. Personalized for you.
84 
Let's personalize your content